(Q34236671)

31 July 2017

1 reference

title

HMG-CoA reductase inhibitors. (English)

1 reference

31 July 2017

Illingworth DR

1

1 reference

PubMed ID

11329860

31 July 2017

Tobert JA

series ordinal

2

1 reference

31 July 2017

1 January 2001

1 reference

Advances in Protein Chemistry

31 July 2017

1 reference

31 July 2017

56

1 reference

31 July 2017

77-114

1 reference

Management of dyslipidemia in adults with diabetes. American Diabetes Association

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Platelet function in hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Lipids and risk of coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Lovastatin and the human lens; results of a two year study. The MSDRL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The low fat/low cholesterol diet is ineffective

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Reductase inhibitor monotherapy and stroke prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Medications and cataract. The Blue Mountains Eye Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Rhabdomyolysis after taking atorvastatin with gemfibrozil

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effects of treatment with lovastatin and pravastatin on daytime cognitive performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Cholesterol reduction yields clinical benefit. A new look at old data

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Cholesterol reduction yields clinical benefit: impact of statin trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effects of combined bezafibrate-simvastatin appraised in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Regression of tendon xanthomas in patients with familial hypercholesterolemia treated with lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

A Randomized Multicenter Trial Comparing and Efficacy of Simvastatin and Fluvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Fluvastatin with and without niacin for hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-blind, placebo-controlled, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Nicotinic acid-associated myopathy: a report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

1 reference

7 January 2021

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Human lens cholesterol concentrations in patients who used lovastatin or simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Carcinogenicity of lipid-lowering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Doubts about preventing coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Ocular drug safety and HMG-CoA-reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The genetic toxicity of human carcinogens and its implications

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Comparison of statins in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Efficacy and long-term adverse effect pattern of lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Clinical experience with lovastatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effect of Cholesterol-Lowering Therapy on Coronary Endothelial Vasomotor Function in Patients With Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Prognostic significance of progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

The effects of pravastatin on hyperlipidemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956003-9

7 January 2021

10.1016/S0065-3233(01)56003-9

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11329860